Response to Office Action

FOR HUMANS. BY SCIENCE.

SEED HEALTH, INC.

Response to Office Action

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011)
OMB No. 0651-0050 (Exp 09/20/2020)

Response to Office Action


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 88622285
LAW OFFICE ASSIGNED LAW OFFICE 116
MARK SECTION
MARK http://uspto.report/TM/88622285/mark.png
LITERAL ELEMENT FOR HUMANS. BY SCIENCE.
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
MARK STATEMENT The mark consists of standard characters, without claim to any particular font style, size or color.
GOODS AND/OR SERVICES SECTION (current)
INTERNATIONAL CLASS 005
DESCRIPTION
Probiotic formulations, namely, capsules for medical purposes, in particular, for producing beneficial metabolites, modulating inflammation, increasing beneficial microbes, and inhibiting pathogens in the human microbiome; dietary supplements; nutritional supplements; probiotic formulations, namely, suppositories and lyophilized powders for medical purposes, in particular, for producing beneficial metabolites, modulating inflammation, increasing beneficial microbes, and inhibiting pathogens in the human microbiome; probiotic and prebiotic formulations, namely, capsules, suppositories, and lyophilized powders for the developing infant gut microbiome, for supporting healthy vaginal microbiomes in pregnant women and supporting healthy breastfeeding, and for increasing strains of beneficial bacteria in infants; pharmaceutical preparations for microbiome dysbiosis resulting from the use of antibiotic medications and consumer health interventions for the restoration of balance to a perturbed human microbiome; heat-killed or pasteurized microbial preparations, substances, and derivatives
FILING BASIS Section 1(b)
GOODS AND/OR SERVICES SECTION (proposed)
INTERNATIONAL CLASS 005
TRACKED TEXT DESCRIPTION
Probiotic formulations, namely, capsules for medical purposes, in particular, for producing beneficial metabolites, modulating inflammation, increasing beneficial microbes, and inhibiting pathogens in the human microbiome; dietary supplements; nutritional supplements; probiotic formulations, namely, suppositories and lyophilized powders for medical purposes, in particular, for producing beneficial metabolites, modulating inflammation, increasing beneficial microbes, and inhibiting pathogens in the human microbiome; probiotic and prebiotic formulations, namely, capsules, suppositories, and lyophilized powders for the developing infant gut microbiome, for supporting healthy vaginal microbiomes in pregnant women and supporting healthy breastfeeding, and for increasing strains of beneficial bacteria in infants; pharmaceutical preparations for microbiome dysbiosis resulting from the use of antibiotic medications and consumer health interventions for the restoration of balance to a perturbed human microbiome; heat-killed or pasteurized microbial preparations, substances, and derivatives; heat-killed or pasteurized microbial preparations, substances, and derivatives for pharmaceutical, nutraceutical, dietetic or nutritional use
FINAL DESCRIPTION
Probiotic formulations, namely, capsules for medical purposes, in particular, for producing beneficial metabolites, modulating inflammation, increasing beneficial microbes, and inhibiting pathogens in the human microbiome; dietary supplements; nutritional supplements; probiotic formulations, namely, suppositories and lyophilized powders for medical purposes, in particular, for producing beneficial metabolites, modulating inflammation, increasing beneficial microbes, and inhibiting pathogens in the human microbiome; probiotic and prebiotic formulations, namely, capsules, suppositories, and lyophilized powders for the developing infant gut microbiome, for supporting healthy vaginal microbiomes in pregnant women and supporting healthy breastfeeding, and for increasing strains of beneficial bacteria in infants; pharmaceutical preparations for microbiome dysbiosis resulting from the use of antibiotic medications and consumer health interventions for the restoration of balance to a perturbed human microbiome; heat-killed or pasteurized microbial preparations, substances, and derivatives for pharmaceutical, nutraceutical, dietetic or nutritional use
FILING BASIS Section 1(b)
SIGNATURE SECTION
RESPONSE SIGNATURE /jeanette sinclare/
SIGNATORY'S NAME Jeanette E. Sinclare
SIGNATORY'S POSITION Attorney of Record, Colorado bar member
DATE SIGNED 01/09/2020
AUTHORIZED SIGNATORY YES
FILING INFORMATION SECTION
SUBMIT DATE Thu Jan 09 18:42:29 EST 2020
TEAS STAMP USPTO/ROA-XX.XXX.XXX.XX-2
0200109184229076704-88622
285-700dad695cda670c14b2b
e43e64799386727cb769b23b5
59ff4a43e170b349f517-N/A-
N/A-20200109182735676355



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011)
OMB No. 0651-0050 (Exp 09/20/2020)

Response to Office Action


To the Commissioner for Trademarks:

Application serial no. 88622285 FOR HUMANS. BY SCIENCE.(Standard Characters, see http://uspto.report/TM/88622285/mark.png) has been amended as follows:

CLASSIFICATION AND LISTING OF GOODS/SERVICES

Applicant proposes to amend the following class of goods/services in the application:
Current: Class 005 for Probiotic formulations, namely, capsules for medical purposes, in particular, for producing beneficial metabolites, modulating inflammation, increasing beneficial microbes, and inhibiting pathogens in the human microbiome; dietary supplements; nutritional supplements; probiotic formulations, namely, suppositories and lyophilized powders for medical purposes, in particular, for producing beneficial metabolites, modulating inflammation, increasing beneficial microbes, and inhibiting pathogens in the human microbiome; probiotic and prebiotic formulations, namely, capsules, suppositories, and lyophilized powders for the developing infant gut microbiome, for supporting healthy vaginal microbiomes in pregnant women and supporting healthy breastfeeding, and for increasing strains of beneficial bacteria in infants; pharmaceutical preparations for microbiome dysbiosis resulting from the use of antibiotic medications and consumer health interventions for the restoration of balance to a perturbed human microbiome; heat-killed or pasteurized microbial preparations, substances, and derivatives
Original Filing Basis:
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to use the mark in commerce on or in connection with the identified goods/services in the application. For a collective trademark, collective service mark, or collective membership mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members on or in connection with the identified goods/services/collective membership organization. For a certification mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that meet the certification standards of the applicant.

Proposed:
Tracked Text Description: Probiotic formulations, namely, capsules for medical purposes, in particular, for producing beneficial metabolites, modulating inflammation, increasing beneficial microbes, and inhibiting pathogens in the human microbiome; dietary supplements; nutritional supplements; probiotic formulations, namely, suppositories and lyophilized powders for medical purposes, in particular, for producing beneficial metabolites, modulating inflammation, increasing beneficial microbes, and inhibiting pathogens in the human microbiome; probiotic and prebiotic formulations, namely, capsules, suppositories, and lyophilized powders for the developing infant gut microbiome, for supporting healthy vaginal microbiomes in pregnant women and supporting healthy breastfeeding, and for increasing strains of beneficial bacteria in infants; pharmaceutical preparations for microbiome dysbiosis resulting from the use of antibiotic medications and consumer health interventions for the restoration of balance to a perturbed human microbiome; heat-killed or pasteurized microbial preparations, substances, and derivatives; heat-killed or pasteurized microbial preparations, substances, and derivatives for pharmaceutical, nutraceutical, dietetic or nutritional useClass 005 for Probiotic formulations, namely, capsules for medical purposes, in particular, for producing beneficial metabolites, modulating inflammation, increasing beneficial microbes, and inhibiting pathogens in the human microbiome; dietary supplements; nutritional supplements; probiotic formulations, namely, suppositories and lyophilized powders for medical purposes, in particular, for producing beneficial metabolites, modulating inflammation, increasing beneficial microbes, and inhibiting pathogens in the human microbiome; probiotic and prebiotic formulations, namely, capsules, suppositories, and lyophilized powders for the developing infant gut microbiome, for supporting healthy vaginal microbiomes in pregnant women and supporting healthy breastfeeding, and for increasing strains of beneficial bacteria in infants; pharmaceutical preparations for microbiome dysbiosis resulting from the use of antibiotic medications and consumer health interventions for the restoration of balance to a perturbed human microbiome; heat-killed or pasteurized microbial preparations, substances, and derivatives for pharmaceutical, nutraceutical, dietetic or nutritional use
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to use the mark in commerce on or in connection with the identified goods/services in the application. For a collective trademark, collective service mark, or collective membership mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members on or in connection with the identified goods/services/collective membership organization. For a certification mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that meet the certification standards of the applicant.

SIGNATURE(S)
Response Signature
Signature: /jeanette sinclare/     Date: 01/09/2020
Signatory's Name: Jeanette E. Sinclare
Signatory's Position: Attorney of Record, Colorado bar member

The signatory has confirmed that he/she is a U.S.-licensed attorney who is an active member in good standing of the bar of the highest court of a U.S. state (including the District of Columbia and any U.S. Commonwealth or territory); and he/she is currently the owner's/holder's attorney or an associate thereof; and to the best of his/her knowledge, if prior to his/her appointment another U.S.-licensed attorney not currently associated with his/her company/firm previously represented the owner/holder in this matter: the owner/holder has revoked their power of attorney by a signed revocation or substitute power of attorney with the USPTO; the USPTO has granted that attorney's withdrawal request; the owner/holder has filed a power of attorney appointing him/her in this matter; or the owner's/holder's appointed U.S.-licensed attorney has filed a power of attorney appointing him/her as an associate attorney in this matter.

        
Serial Number: 88622285
Internet Transmission Date: Thu Jan 09 18:42:29 EST 2020
TEAS Stamp: USPTO/ROA-XX.XXX.XXX.XX-2020010918422907
6704-88622285-700dad695cda670c14b2be43e6
4799386727cb769b23b559ff4a43e170b349f517
-N/A-N/A-20200109182735676355



uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed